For instance, ABY-029, an IRDye800CW labeled anti-EGFR Affibody®, was validated preclinically (Samkoe et al., 2017; 2019) and is currently being employed in a Phase 0 clinical trial in head and neck cancer patients (NCT03282461) (Chen et al., 2023). This evidence concerns the gene EGFR and head and neck cancer.